ftzy.com.cn (PTHL) - Koefisien utang jangka dawa marang modal

Pheton Holdings - logo grafis emiten PTHL

Pheton Holdings Ltd (PTHL) dominates the brachytherapy laser systems niche, leveraging strict regulatory barriers in China. The ratio of long-term loans to equity demonstrates financial stability, where the 0.00 mark characterizes this parameter. The company's software precision minimizes tissue damage, while the deep integration of proprietary software into clinics ensures a steady stream of subscription revenue.

ftzy.com.cn (PTHL): Utang jangka dawa marang ekuitas saka 06.09.2024 nganti 16.01.2026
Produk mawa merek Pheton Holdings Limited

Investors seek asset stability by analyzing the financing structure. Stable B2B revenues from medical software at Pheton Holdings Ltd. (PTHL) enable the efficient servicing of borrowed funds. The long-term debt-to-equity ratio reflects the weight of obligations with maturities exceeding one year relative to equity. This ratio reveals the extent to which business development depends on external lending. Low values confirm the financial autonomy and reliability of the company.

Analisis perusahaan pesaing

Haleon PLC - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal KVUE|VRNA (Verona Pharma Inc.) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal MENS (Jyong Biotech Ltd)|Utang jangka dawa marang modal ligand.com LGND|AMRX - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Liquidia Inc.|GLPG (Galapagos NV) - Utang jangka dawa marang modal|Utang jangka dawa marang modal anipharmaceuticals.com|Rasio utang jangka dawa marang ekuitas MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Pacira PCRX|ARS Corp (SPRY) - Kewajiban jangka dawa marang modal|TBPH: Rasio utang jangka dawa marang ekuitas|aquestive.com - Rasio silihan jangka dawa marang modal|SCPH: Utang jangka dawa marang modal|Tectonic Therapeutic - Koefisien utang jangka dawa marang modal|TNXP (Tonix Pharmaceuticals Inc.) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal SXT China SXTC|Utang jangka dawa marang ekuitas Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas eXoZymes EXOZ|ORMP (Oramed) - Kewajiban jangka dawa marang ekuitas|Entera Bio Corp - Utang jangka dawa marang modal|Koefisien utang jangka dawa marang modal HYFT (MindWalk Therapeutics)|ABVC: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal cumberlandpharma.com (CPIX)|Rasio utang jangka dawa marang ekuitas QNTM|FGEN (FibroGen Inc) - Rasio silihan jangka dawa marang modal|Utang jangka dawa marang ekuitas Telomir Pharma (TELO)|RANI - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas Synergy CHC SNYR|RLYB: Rasio utang jangka dawa marang modal|LEXX: Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PULM (Pulmatrix Inc)|APM: Utang jangka dawa marang modal|Lyra Therapeutics Inc - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Impact BioMedical Inc|Kewajiban jangka dawa marang modal TNF Pharma TNFA|Utang jangka dawa marang ekuitas cbdMD, Inc. (YCBD)|Utang jangka dawa marang ekuitas PRFX (PainReform Ltd)|Utang jangka dawa marang modal CYTO (Altamira Therapeutics Ltd.)|LIPO: Rasio utang jangka dawa marang modal|OptiNose, Inc. - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal pieris.com PIRS|Procaps (PROC) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang modal PTPI|QLI (Qilian International Holding Group Limited) - Utang jangka dawa marang modal|SLRN - Tanggungan utang jangka dawa marang ekuitas|Utang jangka dawa marang ekuitas TFF Pharmaceuticals (TFFP)